Dirk Bender

Dirk Bender

Auto-generated profile, based on publicly available information

Dirk Bender

Aarhus University Hospital

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2016 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
NTNoemie Tentillier
Noemie Tentillier
AEAnders Etzerodt
Anders Etzerodt
MOMads N. Olesen
Mads N. Olesen
FRF. Sila Rizalar
F. Sila Rizalar
JJJan Jacobsen
Jan Jacobsen
MRMarina Romero-Ramos
Marina Romero-Ramos
Increasing evidence supports a decisive role for inflammation in the neurodegenerative process of Parkinson's disease (PD). The immune response in PD seems to involve, not only microglia, but also other immune cells infiltrated into the brain. Indeed, we observed here the infiltration of macrophages, specifically CD163+ macrophages, into the area of neurodegeneration in the 6-hydroxydopamine (6-OHDA) PD model. Therefore, we investigated the therapeutic potential of the infiltrated CD163+ macrophages to modulate local microglia in the brain to achieve neuroprotection. To do so, we designed liposomes targeted for the CD163 receptor to deliver dexamethasone (Dexa) into the CD163+ macrophages in the 6-OHDA PD model. Our data show that a fraction of the CD163-targeted liposomes were carried into the brain after peripheral intravenous injection. The 6-OHDA-lesioned rats that received repeated intravenous CD163-targeted liposomes with Dexa for 3 weeks exhibited better motor performance than the control groups and had minimal glucocorticoid-driven side effects. Furthermore, these animals showed better survival of dopaminergic neurons in substantia nigra and an increased number of microglia expressing major histocompatibility complex II. Therefore, rats receiving CD163-targeted liposomes with Dexa were partially protected against 6-OHDA-induced dopaminergic neurodegeneration, which correlated with a distinctive microglia response. Altogether, our data support the use of macrophages for the modulation of brain neurodegeneration and specifically highlight the potential of CD163-targeted liposomes as a therapeutic tool in PD.SIGNIFICANCE STATEMENTThe immune response now evident in the progression of Parkinson's disease comprises both local microglia and other immune cells. We provide evidence that CD163+ macrophages can be a target to modulate brain immune response to achieve neuroprotection in the 6-hydroxydopamine model. To do so, we targeted the CD163+ population, which to a low but significant extent infiltrated in the neurodegenerating area of the brain. Specially designed liposomes targeted for the CD163 receptor were loaded with glucocorticoids and injected peripherally to modify the infiltrated CD163 cells toward an anti-inflammatory profile. This modification of the CD163 population resulted in a distinctive microglial response that correlated with decreased dopaminergic cell death and better motor performance.

10 January 2022 in Hepatology
Verified
Journal Article
Open access
PDF file
TSThomas Damgaard Sandahl
Thomas Damgaard Sandahl
LGLars Christian Gormsen
Lars Christian Gormsen
KKKristoffer Kjærgaard
Kristoffer Kjærgaard
MVMikkel Holm Vendelbo
Mikkel Holm Vendelbo
DMDitte Emilie Munk
Ditte Emilie Munk
POPeter Ott
Peter Ott
Background and Aims: Wilson’s disease (WD) is a genetic disease with systemic accumulation of copper that leads to symptoms from the liver and brain. However, the underlying defects in copper transport kinetics are only partly understood. We sought to quantify hepatic copper turnover in patients with WD compared with heterozygote and control subjects using PET with copper‐64 (64Cu) as a tracer. Furthermore, we assessed the diagnostic potential of the method. Approach and Results: Nine patients with WD, 5 healthy heterozygote subjects, and 8 healthy controls were injected with an i.v. bolus of 64Cu followed by a 90‐min dynamic PET scan of the liver and static whole‐body PET/CT scans after 1.5, 6, and 20 h. Blood 64Cu concentrations were measured in parallel. Hepatic copper retention and redistribution were evaluated by standardized uptake values (SUVs). At 90 min, hepatic SUVs were similar in the three groups. In contrast, at 20 h postinjection, the SUV in WD patients (mean ± SEM, 31 ± 4) was higher than in heterozygotes (24 ± 3) and controls (21 ± 4; p < 0.001). An SUV‐ratio of hepatic 64Cu concentration at 20 and 1.5 h completely discriminated between WD patients and control groups (p < 0.0001; ANOVA). By Patlak analysis of the initial 90 min of the PET scan, the steady‐state hepatic clearance of 64Cu was estimated to be slightly lower in patients with WD than in controls (p = 0.04). Conclusions: 64Cu PET imaging enables visualization and quantification of the hepatic copper retention characteristic for WD patients. This method represents a valuable tool for future studies of WD pathophysiology, and may assist the development of therapies, and accurate diagnosis.

23 May 2003 in Synapse
Verified
Journal Article
Closed access
PDF file
Svend Borup JensenSvend Borup Jensen
Svend Borup Jensen
DSDonald F. Smith
Donald F. Smith
DBDirk Bender
Dirk Bender
SJSteen Jakobsen
Steen Jakobsen
DPDan Peters
Dan Peters
PCPaul Cumming
Paul Cumming

1 January 2016 in Acta Neurobiologiae Experimentalis
Verified
Journal Article
Open access
MNMette Slot Nielsen
Mette Slot Nielsen
AGAndreas Nørgaard Glud
Andreas Nørgaard Glud
AMArne Møller
Arne Møller
PMPoul Mogensen
Poul Mogensen
DBDirk Bender
Dirk Bender
CBCarsten Reidies Bjarkam
Carsten Reidies Bjarkam
Parkinson’s disease (PD) is a common neurodegenerative disorder, resulting from progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc). Neuroprotective therapies in PD are still not available, perhaps because animal models do not imitate the chronic and progressive nature of the clinical state of PD. To address

5 May 2016 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
HLHans Lou
Hans Lou
ARAstrid Rosenstand
Astrid Rosenstand
DBDavid Brooks
David Brooks
DBDirk Bender
Dirk Bender
SJSteen Jakobsen
Steen Jakobsen
AMArne Møller
Arne Møller
Background: While it has recently been shown that dopamine release stimulates conscious self‐monitoring through the generation of gamma oscillations in medial prefrontal/anterior cingulate cortex, and that the GABAergic system is effective in producing such oscillations, interaction of the two transmitter systems has not been demonstrated in humans. We here hypothesize that dopamine challenge stimulates the GABA system directly in the medial prefrontal/anterior cingulate region in the human brain.Methods: Positron emission tomography (PET) with the GABA receptor α1/α5 subtype ligand [11C] Ro15‐4513 was used to detect changes in GABA receptor availability after clinical oral doses of levodopa in a double blind controlled study.Results: We here provide the first direct evidence for such coupling in the cerebral cortex, in particular in the medial prefrontal anterior cingulate region, by showing that exogenous dopamine decreases [11C] Ro15‐4513 binding widely in the human brain compatible with a fall in α1 subtype availability in GABA complexes due to increased GABA activity.

20 June 2008 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
DSDonald F. Smith
Donald F. Smith
SHSøren Baarsgaard Hansen
Søren Baarsgaard Hansen
SJSteen Jakobsen
Steen Jakobsen
DBDirk Bender
Dirk Bender
HAHélène Audrain
Hélène Audrain
RRRaben Rosenberg
Raben Rosenberg